184 related articles for article (PubMed ID: 17549375)
41. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
42. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis.
Nurmio M; Kallio J; Toppari J; Jahnukainen K
Reprod Toxicol; 2008 Aug; 25(4):442-6. PubMed ID: 18472395
[TBL] [Abstract][Full Text] [Related]
43. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
44. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
Baruchel S; Sharp JR; Bartels U; Hukin J; Odame I; Portwine C; Strother D; Fryer C; Halton J; Egorin MJ; Reis RM; Martinho O; Stempak D; Hawkins C; Gammon J; Bouffet E
Eur J Cancer; 2009 Sep; 45(13):2352-9. PubMed ID: 19505817
[TBL] [Abstract][Full Text] [Related]
45. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
Romeo S; Debiec-Rychter M; Van Glabbeke M; Van Paassen H; Comite P; Van Eijk R; Oosting J; Verweij J; Terrier P; Schneider U; Sciot R; Blay JY; Hogendoorn PC;
Clin Cancer Res; 2009 Jun; 15(12):4191-8. PubMed ID: 19509155
[TBL] [Abstract][Full Text] [Related]
46. PDGF-C and -D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries.
Karvinen H; Rutanen J; Leppänen O; Lach R; Levonen AL; Eriksson U; Ylä-Herttuala S
Eur J Clin Invest; 2009 Apr; 39(4):320-7. PubMed ID: 19292888
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.
Nurmio M; Toppari J; Zaman F; Andersson AM; Paranko J; Söder O; Jahnukainen K
Int J Androl; 2007 Aug; 30(4):366-76; discussion 376. PubMed ID: 17705809
[TBL] [Abstract][Full Text] [Related]
48. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
49. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
51. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
[TBL] [Abstract][Full Text] [Related]
53. Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.
Sleijfer S; Wiemer E; Verweij J
Nat Clin Pract Oncol; 2008 Feb; 5(2):102-11. PubMed ID: 18235442
[TBL] [Abstract][Full Text] [Related]
54. Effects of imatinib mesylate on adenoid cystic carcinomas.
Ochel HJ; Gademann G; Röcken C; Wördehoff H
Anticancer Res; 2005; 25(5):3659-64. PubMed ID: 16101197
[TBL] [Abstract][Full Text] [Related]
55. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
Adams SF; Hickson JA; Hutto JY; Montag AG; Lengyel E; Yamada SD
Gynecol Oncol; 2007 Mar; 104(3):524-8. PubMed ID: 17049587
[TBL] [Abstract][Full Text] [Related]
56. Phase II study of imatinib in advanced chordoma.
Stacchiotti S; Longhi A; Ferraresi V; Grignani G; Comandone A; Stupp R; Bertuzzi A; Tamborini E; Pilotti S; Messina A; Spreafico C; Gronchi A; Amore P; Vinaccia V; Casali PG
J Clin Oncol; 2012 Mar; 30(9):914-20. PubMed ID: 22331945
[TBL] [Abstract][Full Text] [Related]
57. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
58. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
59. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
60. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.
Cossu-Rocca P; Contini M; Uras MG; Muroni MR; Pili F; Carru C; Bosincu L; Massarelli G; Nogales FF; De Miglio MR
Int J Gynecol Pathol; 2012 Nov; 31(6):570-9. PubMed ID: 23018215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
